< Back to all clusters
[HEALTH] · United States, United Kingdom · 16 sources

started · updated

Shingrix vaccine linked to lower dementia and cardiovascular risks

Recent large-scale studies suggest that the recombinant shingles vaccine, Shingrix, provides significant health benefits beyond preventing the herpes zoster virus. Research published in Nature Medicine by the University of Oxford indicates that recipients of Shingrix experienced a 9% reduction in cardiovascular disease burden over seven years compared to those who received the older, live-attenuated Zostavax vaccine. Specific findings include a 10% reduction in coronary heart disease, a 12% reduction in heart failure, and a 12% reduction in stroke risk among men.

Additionally, a study from Brown University involving over 500,000 individuals found that Shingrix is associated with a 24% lower risk of dementia in older adults. Another U.S. study highlighted the vaccine's effectiveness for patients with multiple sclerosis, noting it reduced shingles risk by up to 81% depending on insurance type.

Researchers utilized a natural experiment approach in the U.S., comparing groups vaccinated just before and after the 2017 transition from Zostavax to Shingrix to minimize healthy vaccine bias. While these observational studies show strong associations, experts note that clinical trials are required to confirm direct causality.

Entities

Brown University · GlaxoSmithKline · Maxime Taquet · NHS · Nature Medicine · Shingrix · TriNetX · University of Oxford · Zostavax

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

17 days ago